With a focus in the fast-growing world of next generation sequencing, Kailos Genetics, through its CLIA Services Laboratory, analyzes DNA for “genetic clues” associated with drug response, adverse response and diagnosis of disease. These clues enable physicians to proactively identify responders and non-responders to certain drug therapies, avoid serious adverse drug reactions that are genetically linked, and diagnose inherited and non-inherited diseases.